Pub. Date : 2019
PMID : 29119932
16 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Relevance of CYP2C9 Function in Valproate Therapy. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 2 | METHODS: CYP2C9 mediated oxidation of valproate, which is the minor metabolic pathway in adults, appears to become the principal route in children. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 3 | Genetic and non-genetic variations in CYP2C9 activity can result in significant inter- and intra-individual differences in valproate pharmacokinetics and valproate induced adverse reactions. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 4 | Genetic and non-genetic variations in CYP2C9 activity can result in significant inter- and intra-individual differences in valproate pharmacokinetics and valproate induced adverse reactions. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 5 | RESULTS: The loss-of-function alleles, CYP2C9*2 or CYP2C9*3, display significant reduction in valproate metabolism in children; furthermore, low CYP2C9 expression in patients with CYP2C9*1/*1 genotype also leads to a decrease in valproate metabolizing capacity. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 6 | RESULTS: The loss-of-function alleles, CYP2C9*2 or CYP2C9*3, display significant reduction in valproate metabolism in children; furthermore, low CYP2C9 expression in patients with CYP2C9*1/*1 genotype also leads to a decrease in valproate metabolizing capacity. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 7 | RESULTS: The loss-of-function alleles, CYP2C9*2 or CYP2C9*3, display significant reduction in valproate metabolism in children; furthermore, low CYP2C9 expression in patients with CYP2C9*1/*1 genotype also leads to a decrease in valproate metabolizing capacity. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 8 | RESULTS: The loss-of-function alleles, CYP2C9*2 or CYP2C9*3, display significant reduction in valproate metabolism in children; furthermore, low CYP2C9 expression in patients with CYP2C9*1/*1 genotype also leads to a decrease in valproate metabolizing capacity. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 9 | RESULTS: The loss-of-function alleles, CYP2C9*2 or CYP2C9*3, display significant reduction in valproate metabolism in children; furthermore, low CYP2C9 expression in patients with CYP2C9*1/*1 genotype also leads to a decrease in valproate metabolizing capacity. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 10 | RESULTS: The loss-of-function alleles, CYP2C9*2 or CYP2C9*3, display significant reduction in valproate metabolism in children; furthermore, low CYP2C9 expression in patients with CYP2C9*1/*1 genotype also leads to a decrease in valproate metabolizing capacity. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 11 | RESULTS: The loss-of-function alleles, CYP2C9*2 or CYP2C9*3, display significant reduction in valproate metabolism in children; furthermore, low CYP2C9 expression in patients with CYP2C9*1/*1 genotype also leads to a decrease in valproate metabolizing capacity. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 12 | RESULTS: The loss-of-function alleles, CYP2C9*2 or CYP2C9*3, display significant reduction in valproate metabolism in children; furthermore, low CYP2C9 expression in patients with CYP2C9*1/*1 genotype also leads to a decrease in valproate metabolizing capacity. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 13 | CONCLUSION: Novel strategy for valproate therapy adjusted to CYP2C9-status (CYP2C9 genotype and CYP2C9 expression) is strongly recommended in childhood. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 14 | CONCLUSION: Novel strategy for valproate therapy adjusted to CYP2C9-status (CYP2C9 genotype and CYP2C9 expression) is strongly recommended in childhood. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 15 | CONCLUSION: Novel strategy for valproate therapy adjusted to CYP2C9-status (CYP2C9 genotype and CYP2C9 expression) is strongly recommended in childhood. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |
| 16 | The early knowledge of pediatric patients" CYP2C9-status facilitates the optimization of valproate dosing which contributes to the avoidance of misdosing induced adverse reactions, such as abnormal blood levels of ammonia and alkaline phosphatase, and improves the safety of children"s anticonvulsant therapy. | Valproic Acid | cytochrome P450 family 2 subfamily C member 9 | Homo sapiens |